There’s more to discover with VELCADE® (bortezomib)

VELCADE (bortezomib) is approved for the treatment of people with multiple myeloma (a cancer of the plasma cells). Before you receive treatment with VELCADE, tell your doctor about all of your medical conditions. You should not receive VELCADE if you are allergic to bortezomib, boron, or mannitol. VELCADE must not be administered into your spinal fluid (intrathecally).

Please read the Important Safety Information for VELCADE on pages 22-23 and accompanying full Prescribing Information.
“Staying on treatment is just part of my life right now—even though it’s meant postponing my trip to Mexico. My doctor let me know that it could take weeks or months for the myeloma to respond. And as long as he tells me that I need to keep trying, I will.”

RAFAEL living with multiple myeloma

Please read the Important Safety Information for VELCADE on pages 22-23 and accompanying full Prescribing Information.
Your doctor has prescribed VELCADE (bortezomib) to treat your multiple myeloma. You probably have many questions regarding multiple myeloma and VELCADE. This booklet is designed to give you information that may be helpful to start finding answers and information.

Throughout this booklet are stories of people just like you. People who were overwhelmed at first. Scared and confused about their diagnosis and beginning treatment.

And, like them, you will learn about the disease, learn about treatment with VELCADE, and discover resources and tools that may help you.

This booklet is not meant to replace conversations with your healthcare team. If you have any questions or would like some additional information, you should speak with your doctor or nurse.

You can also visit VELCADE.com and sign up to receive informative emails.
“Getting diagnosed with multiple myeloma began a complicated journey. I admit I’m not the person I was since my diagnosis. I don’t feel the same and I don’t have the same priorities. But, I learned more about the disease, and I’m figuring out the journey. I have a life that I love. I know I still have more to learn.”

Please read the Important Safety Information for VELCADE on pages 22-23 and accompanying full Prescribing Information.

VELCADE is not indicated for pediatric patients.
MULTIPLE MYELOMA. Getting the facts

Multiple myeloma is a cancer of the blood. Some people with multiple myeloma have many symptoms, while others have few, if any. Common signs and symptoms of multiple myeloma may include: bone pain and broken bones, nausea and vomiting, fatigue, frequent infections, nervous system problems, anemia, and hypercalcemia.

These symptoms may be referred to as CRAB: C=elevated Calcium, R=Renal (kidney) problems, A=Anemia, B=Bone lesions.

Multiple myeloma affects the part of your bone called bone marrow. Your blood is produced in your bone marrow, which is made up of many different types of cells, including red blood cells, white blood cells, platelets, and plasma cells.

A plasma cell is a type of white blood cell that normally produces antibodies to fight infections. If you have multiple myeloma, you have abnormal plasma cells, also called myeloma cells. These myeloma cells push out normal cells. They form tumors in bones and, sometimes, in various soft tissues of the body.

Myeloma cells can collect over time and build up in the bone marrow. When they do, they prevent bone marrow from making enough blood cells for the body to fight infection and other diseases.

Although multiple myeloma is not curable, there are many treatment options available to you.

For more information, please visit VELCADE.com
“I have lots of hobbies, like puttering around with my cars. I’m also a self-proclaimed workaholic and love making lists. When I started treatment, I tracked my symptoms and how I was feeling. Recording my treatment and focusing on my personal goals kept me motivated. And I still have more to accomplish.”

TONY living with multiple myeloma

Please read the Important Safety Information for VELCADE on pages 22-23 and accompanying full Prescribing Information.
How VELCADE® (bortezomib) works

VELCADE (bortezomib) is a type of chemotherapy called a targeted therapy. It is approved by the FDA for the treatment of people with multiple myeloma. VELCADE is part of a class of drugs called proteasome inhibitors.

Cancer cells divide and multiply more rapidly than most other cells. The goal of VELCADE treatment is to target cancer cells and stop them from growing and multiplying.

VELCADE may be administered as a subcutaneous or intravenous (IV) injection. Both ways are administered in a doctor’s office or at a clinic.

- Subcutaneous VELCADE is injected under the skin
- IV VELCADE is injected into a vein, which may be referred to as an IV injection

VELCADE must not be administered into your spinal fluid (intrathecally).
“A lot changed when I started treatment with VELCADE. The adjustment wasn’t easy and I leaned on my wife and our kids for support. I couldn’t have done it without my family. And now we all have more to fight for.”

Rafael living with multiple myeloma

Please read the Important Safety Information for VELCADE on pages 22-23 and accompanying full Prescribing Information.
VELCADE® (bortezomib): Proven to help people with multiple myeloma live longer

At the 5-year evaluation of a clinical trial, people receiving VELCADE (bortezomib) plus melphalan+prednisone (MP) lived longer than people receiving MP alone.

In this trial, people who received VELCADE-based therapy for about 1 year* lived longer than those whose treatment did not include VELCADE. For this reason, it’s important to stick with your treatment plan.

A good response is a good reason to stay on therapy.

- 69% of people responded with VELCADE-based therapy
- 30% of people receiving VELCADE achieved a complete response
- 28% of people (1 out of every 4) achieved a complete response after 24 weeks of VELCADE-based therapy

11% of people receiving VELCADE and 10% of people receiving MP stopped treatment because of side effects.

In this clinical trial, the most commonly reported side effects included abnormal blood cell counts; numbness, tingling, burning, or weakness in hands or feet (peripheral neuropathy); nausea; diarrhea; and nerve pain.

*Half of the people on VELCADE-based therapy continued to receive VELCADE for at least 50 weeks out of a planned 54 weeks.

In the trial, VELCADE was given with 2 medications, MP, and was compared with MP alone. A total of 682 people who had never been treated before and were not eligible for a stem cell transplant participated.
“After Melvin received his diagnosis, his positive attitude took a hit. But, we both put on our game faces, and met it head on. When, midway through treatment the myeloma started to respond and his doctor advised he stay with it, I supported him. He admits this is the toughest thing he’s ever done. But I know he still has more to give.”

CLAUDIA  Melvin’s wife and caregiver

Please read the Important Safety Information for VELCADE on pages 22-23 and accompanying full Prescribing Information.
TREATMENT GOAL: **Plan to stay on VELCADE® (bortezomib) for 1 year**

- VELCADE may be given twice weekly for 6 months. Then it may be given once weekly for the next 6 months
- Half of the people on VELCADE-based therapy continued to receive VELCADE for at least 50 weeks out of a planned 54 weeks
- In a clinical trial, VELCADE was given in combination with MP, according to this schedule:

  - **Cycles 1-4**
    - **Twice Weekly, 6-Week Cycles**
    - 1, 2, 3, 4, 5, 6, 7
      - 8, 9, 10, 11, 12, 13, 14
      - 15, 16, 17, 18, 19, 20, 21
      - 22, 23, 24, 25, 26, 27, 28
      - 29, 30, 31, 32, 33, 34, 35
      - 36, 37, 38, 39, 40, 41, 42

  - **Cycles 5-9**
    - **Once Weekly, 6-Week Cycles**
    - ▼ VELCADE □ ORAL MP

Ask your doctor about your risk for shingles before starting treatment with VELCADE.

Create your own personalized treatment calendar by visiting VELCADEtools.com
“Tony never talks about his problems, so it wasn’t easy for him to tell his doctor about side effects. So, I joined him at his appointments to help him open up. It sure did help the doctor to know exactly what Tony was experiencing. And now Tony continues to have more to share.”

BEVERLY
Tony’s wife and caregiver
Side effects you may experience while receiving VELCADE® (bortezomib)

It is important to talk openly about symptoms or side effects you may be experiencing

Everyone’s experience with treatment is different. You may have some, all, or none of these side effects.

In a study of VELCADE (bortezomib) in combination with MP versus MP alone, the most commonly reported side effects with VELCADE were:

- Abnormal blood cell counts (neutropenia, leukopenia, thrombocytopenia)
- Tingling, burning, or weakness in hands or feet (peripheral neuropathy)
- Nausea
- Diarrhea
- Nerve pain

You can download and fill out a neurotoxicity assessment tool to help your healthcare team evaluate peripheral neuropathy at VELCADE.com

If you experience any side effects with VELCADE, tell your doctor or nurse right away. By monitoring how you feel, your healthcare team may decide to reduce, change, or stop your dose of VELCADE.

It’s important to understand that in a clinical trial, the number of new side effects was lower after 6 months of VELCADE-based therapy.

For more information, please visit VELCADE.com
“When I was first diagnosed, there were so many questions. You not only have to find the right treatment, but you have to get the right resources, too. And as they say, you just have to keep on trucking. Make the best of everything. Because I have more to see.”

Please read the Important Safety Information for VELCADE on pages 22-23 and accompanying full Prescribing Information.
What if you need help paying for VELCADE® (bortezomib)?

VRAP (VELCADE Reimbursement Assistance Program) can help you:

• Understand insurance and coverage*
• Find alternative and supplemental insurance coverage options

VRAP also has information on co-pay foundations, which offer financial assistance with:

• Prescription drug co-insurance, co-pays, and deductibles
• Health insurance premiums
• Other select out-of-pocket healthcare costs

Foundations

There are various foundations and organizations that serve as valuable resources for receiving additional support.

See Tools & Resources on VELCADE.com for a list, and contact those organizations directly for information about their specific programs and offerings.

What if you don’t have insurance coverage?

Free medication can be delivered to healthcare providers for people who qualify.†
Call 1-866-VELCADE (option 2) or visit VELCADEafford.com to find out more about patient assistance.

*VRAP does not file claims or appeal claims for callers, and it cannot guarantee that you will be successful in obtaining reimbursement.

†The patient assistance program will reimburse up to a 12-month supply of VELCADE (bortezomib) if enrolled people lose their insurance and continue to receive care.
“My decision to retreat wasn’t hard. I had a good response during my initial treatment. And this time I was going to receive my medication as a shot and not an IV. My doctor had a different way of giving me VELCADE. I’m glad there were other options for me. Because I have more to dream.”

DELOIS (DEE) living with multiple myeloma

Please read the Important Safety Information for VELCADE on pages 22-23 and accompanying full Prescribing Information.
If VELCADE (bortezomib) worked for you before, it may work for you again

If you have achieved a response with VELCADE and your multiple myeloma came back more than 6 months later, retreatment can offer an additional benefit.

3 in 8 people responded to retreatment with VELCADE

This benefit lasted about 6.5 months*

*Half the patients’ responses lasted less than 6.5 months and half the patients’ responses lasted more than 6.5 months.

In a clinical trial, 130 people who had multiple myeloma that had come back (relapsed) at least 6 months after having achieved a benefit with VELCADE received VELCADE again. Patients received VELCADE with or without dexamethasone.

In this clinical trial, the most common side effects were abnormal levels of blood cells as determined by regular blood tests; and numbness, tingling, burning, or weakness in hands or feet (peripheral neuropathy).

Download a discussion guide from VELCADEtools.com for a helpful list of questions to ask your doctor.
Your retreatment schedule with VELCADE® (bortezomib) may be different from your original treatment schedule

• You may be treated with VELCADE (bortezomib) again for up to 6 months

• In a clinical trial, VELCADE retreatment was given twice a week for 2 weeks, followed by a 10-day rest period. This was repeated up to 8 times (about 6 months)

RETREATMENT CYCLES 1-8

TWICE WEEKLY, 3 WEEKS x 8 (MAXIMUM)

1  2  3  4  5  6  7  8  9  10  11  12  13  14
15 16 17 18 19 20 21

• Your doctor may start your retreatment with VELCADE at the last dose you were receiving VELCADE

  – Your doctor may consider starting you on subcutaneous VELCADE if you have numbness, tingling, burning, or weakness in your hands or feet (peripheral neuropathy) or are at high risk for these symptoms

• It’s essential to take treatment as prescribed by your healthcare team

Please read the Important Safety Information for VELCADE on pages 22-23 and accompanying full Prescribing Information.
While receiving VELCADE (bortezomib), it’s important to speak up about how you feel

13% of patients stopped treatment due to side effects.

In a clinical trial of retreatment with VELCADE, the most common side effects were:

- Abnormal blood cell counts (neutropenia, leukopenia, thrombocytopenia)
- Tingling, burning, or weakness in hands or feet (peripheral neuropathy)

Side effects did not get worse with retreatment.

When starting retreatment, be sure to talk to your doctor about any other health condition you have or medications you’re taking.

If you have any side effects with VELCADE, tell your doctor or nurse right away.

Your healthcare team might decide to change your dose or schedule of VELCADE to help you stay on treatment.

Ask your doctor about your risk for shingles before starting treatment with VELCADE.
VELCADE is not indicated for pediatric patients.

“Arm yourself with as much information as you can. Network with people. Stay in touch with your family or join a support group. I can’t say that everything has been a joyride for me, but when I need support, I know where to get it. Because I have more to ask.”

Please read the Important Safety Information for VELCADE on pages 22-23 and accompanying full Prescribing Information.
Where to find additional personal support

Many foundations and organizations offer valuable transportation and financial support. Please contact the organizations listed below directly for more information about their specific programs and offerings.

<table>
<thead>
<tr>
<th>Organization</th>
<th>Phone</th>
<th>Website</th>
</tr>
</thead>
<tbody>
<tr>
<td>American Cancer Society</td>
<td>1-800-227-2345 cancer.org</td>
<td></td>
</tr>
<tr>
<td>Association of Cancer Online Resources</td>
<td>212-226-5525 acor.org</td>
<td></td>
</tr>
<tr>
<td>CancerCare, Inc.</td>
<td>1-800-813-4673 cancercare.org</td>
<td></td>
</tr>
<tr>
<td>Cancer Support Community</td>
<td>1-888-793-9355 cancersupportcommunity.org</td>
<td></td>
</tr>
<tr>
<td>Chronic Disease Fund (CDF)</td>
<td>1-877-968-7233 gooddaysfromcdf.org</td>
<td></td>
</tr>
<tr>
<td>International Myeloma Foundation (IMF)</td>
<td>1-800-452-2873 myeloma.org</td>
<td></td>
</tr>
<tr>
<td>The Leukemia &amp; Lymphoma Society (LLS)</td>
<td>1-800-955-4572 lls.org</td>
<td></td>
</tr>
<tr>
<td>Multiple Myeloma Research Foundation (MMRF)</td>
<td>1-203-229-0464 themmrf.org</td>
<td></td>
</tr>
<tr>
<td>National Cancer Institute</td>
<td>1-800-422-6237 cancer.gov</td>
<td></td>
</tr>
<tr>
<td>National Coalition for Cancer Survivorship (NCCS)</td>
<td>1-877-622-7937 canceradvocacy.org</td>
<td></td>
</tr>
<tr>
<td>National Organization for Rare Disorders (NORD)</td>
<td>1-203-744-0100 rarediseases.org</td>
<td></td>
</tr>
<tr>
<td>Patient Access Network Foundation (PANF)</td>
<td>1-866-316-PANF (7263) panfoundation.org</td>
<td></td>
</tr>
<tr>
<td>Patient Advocate Foundation (PAF)</td>
<td>1-800-532-5274 patientadvocate.org</td>
<td></td>
</tr>
</tbody>
</table>
Indication and Important Safety Information for VELCADE® (bortezomib)

What is VELCADE used for?
VELCADE (bortezomib) is approved for the treatment of people with multiple myeloma (a cancer of the plasma cells).

How is VELCADE administered?
VELCADE is prescribed by a doctor experienced in the use of medications to treat cancer. It is administered by a healthcare professional as an injection into your vein (intravenously, or IV) or under your skin (subcutaneously). VELCADE must not be administered into your spinal fluid (intrathecally).

Who should not receive VELCADE?
Before you receive treatment with VELCADE, tell your doctor about all of your medical conditions. You should not receive VELCADE if you are allergic to bortezomib, boron, or mannitol.

What are the possible side effects of VELCADE?
VELCADE can cause serious side effects, including:

- **Peripheral neuropathy.** VELCADE can cause damage to the nerves, a condition called peripheral neuropathy. You may feel muscle weakness, tingling, burning, pain, and loss of feeling in your hands and feet, any of which can be severe. Tell your doctor if you notice any of these symptoms. Your doctor may change the dose and/or schedule of VELCADE or stop it altogether. If you have peripheral neuropathy before starting VELCADE, your doctor could consider giving you VELCADE subcutaneously.

- **Low blood pressure.** VELCADE can cause a drop in blood pressure. Tell your doctor if you have low blood pressure, feel dizzy, or feel as though you might faint. If you are taking drugs that lower blood pressure, your medications might need to be adjusted. If you are not drinking enough liquids, your doctor may need to administer IV fluids.

- **Heart problems.** Treatment with VELCADE can cause or worsen heart rhythm problems and heart failure. Your doctor may closely monitor you if you have, or are at risk for, heart disease. Tell your doctor if you experience chest pressure or pain, palpitations, swelling of your ankles or feet, or shortness of breath.

- **Lung problems.** There have been reports of lung disorders in people receiving VELCADE. Some of these events have been fatal. Tell your doctor if you experience any cough, shortness of breath, wheezing, or difficulty breathing.

- **Liver problems.** If you have liver problems, it can be harder for your body to get rid of VELCADE. VELCADE has caused sudden liver failure in people who were taking many medications or had other serious medical conditions. Symptoms of liver problems include a yellow discoloration of the eyes and skin (jaundice) and changes in liver enzymes measured in blood tests. Your doctor will closely monitor you if you have liver disease.

- **Posterior reversible encephalopathy syndrome (PRES).** There have been reports of a rare, reversible condition involving the brain, called PRES, in people treated with VELCADE. People with PRES can have seizures, high blood pressure, headaches, tiredness, confusion, blindness, or other vision problems. Treatment with VELCADE should be stopped in cases of PRES.
• **Gastrointestinal problems.** VELCADE treatment can cause nausea, vomiting, diarrhea, and constipation. If your symptoms are severe, your doctor may recommend IV fluids and/or medications.

• **Neutropenia (low levels of neutrophils, a type of white blood cell).** VELCADE can cause low levels of white blood cells (infection-fighting cells). If your white blood cells become low, you can be at higher risk for infections. Tell your doctor if you develop a fever or believe you have an infection.

• **Thrombocytopenia (low levels of platelets).** VELCADE can cause low levels of platelets (clot-forming cells). If platelets become very low, there is an increased risk of bleeding. Your doctor may recommend a platelet transfusion or other supportive care. You will have regular blood tests to check your cell counts during your treatment with VELCADE. If the number of these cells is very low, your doctor may change the dose and/or schedule of VELCADE.

• **Tumor lysis syndrome (TLS).** TLS is a syndrome that causes a chemical imbalance in the blood that could lead to heart and/or kidney problems. TLS can occur with cancer treatments, and your doctor will be monitoring your blood and urine for any signs of this syndrome. If you develop TLS, your doctor will take appropriate steps to treat it.

More than 1 in 5 people (20%) receiving VELCADE have experienced the following side effects in one or more clinical trials of multiple myeloma: nausea, diarrhea, peripheral neuropathy, thrombocytopenia, neutropenia, fatigue, neuralgia (nerve pain), anemia, leukopenia (low levels of white blood cells), constipation, vomiting, lymphopenia (low levels of a certain type of white blood cells), pyrexia (fever), and anorexia.

**What other information should you discuss with your doctor?**

Women should avoid becoming pregnant or breast-feeding while being treated with VELCADE. Tell your doctor immediately if you think you are pregnant. Discuss with your doctor when it is safe to restart breast-feeding after finishing your treatment.

**You should also tell your doctor if you:**

• Have kidney disease. If you are on dialysis, your doctor will administer VELCADE after the dialysis procedure.

• Are taking medication for diabetes. VELCADE can affect your blood glucose levels. Your doctor may require close monitoring of your blood glucose levels and change the dose of your diabetes medicine while you are being treated with VELCADE.

• Have liver disease.

• Are using any other medications, including prescription and nonprescription medications, herbal or dietary supplements, or holistic treatments. St. John’s wort should be avoided.

• Develop a rash of any type or have skin pain while receiving VELCADE.

The side effects of VELCADE may impair your ability to drive or operate machinery. These are not all of the possible side effects with VELCADE. It is important to always contact your doctor if you experience any side effects while on VELCADE. If you have any questions about VELCADE, contact your doctor. Additional information is available on the website at VELCADE.com.

**Please read the full Prescribing Information for VELCADE enclosed.**
You knew the journey would be tough

but you are even tougher

VELCADE® (bortezomib) support services may be able to direct you to financial, treatment, and personal support, including transportation referral assistance.

Call 1-866-VELCADE and select option 2 to speak to a dedicated case manager:

• If you have concerns about the cost of treatment or need to find legal services
• If you’re looking to stay up to date and get the right information about your treatment
• If you need referrals to organizations that can help you get to and from your medical appointments
• If you want to connect with counseling and support programs or resources that can offer emotional support

Case managers are available Monday through Friday, 8 AM to 8 PM ET.

Please read the Important Safety Information for VELCADE on pages 22-23 and accompanying full Prescribing Information.
Please see full Prescribing Information at

velcade.com/Files/PDFs/VELCADE_PRESCRIBING_INFORMATION.pdf